Arcturus Therapeutics: Q3 Earnings Insights
Portfolio Pulse from Benzinga Insights
Arcturus Therapeutics (NASDAQ:ARCT) reported Q3 earnings with an EPS of $-0.61, beating the estimate of $-1.69 by 63.91%. Revenue increased by $31.77 million from the same period last year. In the previous quarter, a miss on EPS resulted in a 19.22% share price drop the following day. The company's past earnings performance shows variability in meeting EPS and revenue estimates.
November 14, 2023 | 9:45 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Arcturus Therapeutics reported a strong Q3 earnings beat with an EPS of $-0.61 against an estimate of $-1.69 and a significant increase in revenue compared to last year.
Arcturus Therapeutics' earnings beat and revenue increase are likely to be viewed positively by investors, potentially leading to a short-term increase in stock price. Historical data shows that the company's stock price is sensitive to earnings performance, as seen by the 19.22% drop after the last quarter's miss. However, given the variability in past performance, investor reactions may be tempered.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100